Standard and emerging therapies for metastatic differentiated thyroid cancer. - Test2 - elhamkhani - TriplyDB

Standard and emerging therapies for metastatic differentiated thyroid cancer.

Standard and emerging therapies for metastatic differentiated thyroid cancer.

http://www.wikidata.org/entity/Q35583906

about

The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma.Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer Thyroglossal duct remnant carcinoma: beyond the Sistrunk procedure.Nuclear factor-kappa B inhibition can enhance apoptosis of differentiated thyroid cancer cells induced by 131I.Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.Pituitary metastases from papillary carcinoma of thyroid: a case report and literature review.The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors.Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.When thyroid carcinoma goes bad: a morphological and molecular analysis.Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.CTLA-4 gene polymorphisms associate with efficacy of postoperative radioiodine-131 for differentiated thyroid carcinoma.Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas.Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing Vitamin A, endocrine tissues and hormones: interplay and interactions.Therapeutic response and long-term outcome of differentiated thyroid cancer with pulmonary metastases treated by radioiodine therapy.Clinical guidance for radioiodine refractory differentiated thyroid cancer.Pulmonary metastasectomy for thyroid cancer as salvage therapy for radioactive iodine-refractory metastases.

P2860

Q27023157-261F00B7-91E3-4A60-A271-CF3FA18B9780 Q33397349-64CBF2B9-ECE3-4DD4-80E4-BF9D43A01B8B Q33669803-46E17394-8A96-4E0E-9148-0D3A5988B1E0 Q34112103-630D9007-878F-4ED3-B4C0-C98D025A4731 Q34206340-2AAA9E5E-BB73-4D68-92C5-24ABCF2C5E06 Q36366960-8CC67664-98B9-4DAD-A7FA-D05F15A92028 Q37066917-4327667D-C57C-44D7-8676-48CA78B9470A Q37579887-F996D0E1-21AF-485A-AE56-CFC267ABECED Q37729290-B11FE40B-F378-49C7-899D-4F04EFD0B698 Q37988566-797EF9B0-1E17-4610-A25D-32101D6D3126 Q38389256-5C6F2B77-A693-4663-A1D4-6AF815624844 Q38675367-9890F26A-B714-4EC0-AA23-07837EEBCEBE Q38741785-6BA71FFA-D449-44F9-9304-FD6FE3A75173 Q39210485-77869785-FDED-4D9C-9C1B-B93FFBEDD85D Q39274305-47605F87-859E-460C-8093-EB41D9B154ED Q39442677-35CC21E2-A02D-4B71-925F-3907684F0B4E Q46205309-FE8B1612-767E-46E4-8C11-EE87FB91A58D Q47863818-DF8EA870-3AE6-4AA6-970F-A71539522C43 Q50221706-699BF0A2-164B-4C51-B522-409F04F53DEA

P2860

Standard and emerging therapies for metastatic differentiated thyroid cancer.

http://www.wikidata.org/entity/Q35583906

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Standard and emerging therapies for metastatic differentiated thyroid cancer.

@ast

Standard and emerging therapies for metastatic differentiated thyroid cancer.

@en

type

label

Standard and emerging therapies for metastatic differentiated thyroid cancer.

@ast

Standard and emerging therapies for metastatic differentiated thyroid cancer.

@en

prefLabel

Standard and emerging therapies for metastatic differentiated thyroid cancer.

@ast

Standard and emerging therapies for metastatic differentiated thyroid cancer.

@en

P1433

Q35583906-0FE875D9-1C06-48F4-B008-E1EB0BCEE54B

P1476

Q35583906-19B1D9D2-C9BF-4C65-BF3E-4BC6E7F33936

P2093

Q35583906-28D919FF-D7FB-4AA5-8155-AC1097586C73

Q35583906-B9506FDE-BC27-4CDA-8A0E-A7DA8980BB12

Q35583906-BFB626DA-B6C7-4825-A0C5-BB7A85007C4A

Q35583906-F05ED67F-276C-43C2-BC67-039E9405C1D9

P2860

Q35583906-0257E74F-C114-49D3-BEC8-590071CA649B

Q35583906-03BD9C7B-9604-4940-BD56-0B0D83F2B01F

Q35583906-0E76F452-C382-4B95-B089-E78AB676C02C

Q35583906-0EEDB6E1-C990-4FBB-9E86-E8098AEF5945

Q35583906-133C6D1D-D2E4-4647-85A9-59ADF63FEDEB

Q35583906-14EADB38-09F9-44A8-A240-FEDA7BF265CC

Q35583906-16677407-A0FE-4053-937F-AC09519F5803

Q35583906-16A673DD-AAA9-40C4-842B-6DB503493940

Q35583906-1795DFE3-5BEA-4F9F-8DA7-ADDB2D03B93E

Q35583906-17E7CEC3-71FD-4C71-8048-256717314346

P304

Q35583906-A92F6F70-93C9-4850-8FB4-6DEEBCEE4FA7

P31

Q35583906-DD0C7C4E-5ACF-4E40-8B35-1DDF2F484C48

P356

Q35583906-1C976D6C-8DAC-4597-85AA-1754204116EB

P433

Q35583906-6E995BAD-C887-4B42-B067-0EE736C78DB4

P478

Q35583906-4B5FFEE4-1CDB-4B86-B5F9-D6206808176C

P577

Q35583906-9720E5C1-F8A0-43EC-ACE0-9708E5E790E1

P5875

Q35583906-8607F130-4A84-46EA-B00C-DC25397AECB6

P698

Q35583906-EBCDDF8B-25E8-4DC9-8CD1-B0C81E149B3A

P932

Q35583906-9D2D5F38-E810-4741-92F1-45607D1B4E52

P356

THEONCOLOGIST.2009-0190

P1433

P1476

Standard and emerging therapies for metastatic differentiated thyroid cancer.

@en

P2093

Christine J O'Neill

http://www.w3.org/2001/XMLSchema#string

Diana Learoyd

http://www.w3.org/2001/XMLSchema#string

Jennifer Oucharek

http://www.w3.org/2001/XMLSchema#string

Stan B Sidhu

http://www.w3.org/2001/XMLSchema#string

P2860

Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Thoracic metastasectomy for thyroid malignancies

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Thoracic metastasectomy in thyroid malignancies.

P304

146-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2009-0190

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41416669

http://www.w3.org/2001/XMLSchema#string

P698

20142332

http://www.w3.org/2001/XMLSchema#string

P932

3227939

http://www.w3.org/2001/XMLSchema#string